Tag Archives: biomedical

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots

#437554 Ending the COVID-19 Pandemic

Photo: F.J. Jimenez/Getty Images

The approach of a new year is always a time to take stock and be hopeful. This year, though, reflection and hope are more than de rigueur—they’re rejuvenating. We’re coming off a year in which doctors, engineers, and scientists took on the most dire public threat in decades, and in the new year we’ll see the greatest results of those global efforts. COVID-19 vaccines are just months away, and biomedical testing is being revolutionized.

At IEEE Spectrum we focus on the high-tech solutions: Can artificial intelligence (AI) be used to diagnose COVID-19 using cough recordings? Can mathematical modeling determine whether preventive measures against COVID-19 work? Can big data and AI provide accurate pandemic forecasting?

Consider our story “AI Recognizes COVID-19 in the Sound of a Cough,” reported by Megan Scudellari in our Human OS blog. Using a cellphone-recorded cough, machine-learning models can now detect coronavirus with 90 percent accuracy, even in people with no symptoms. It’s a remarkable research milestone. This AI model sifts through hundreds of factors to distinguish the COVID-19 cough from those of bronchitis, whooping cough, and asthma.

But while such high-tech triumphs give us hope, the no-tech solutions are mostly what we have to work with. Soon, as our Numbers Don’t Lie columnist, Vaclav Smil, pointed out in a recent email, we will have near-instantaneous home testing, and we will have an ability to use big data to crunch every move and every outbreak. But we are nowhere near that yet. So let’s use, as he says, some old-fashioned kindergarten epidemiology, the no-tech measures, while we work to get there:

Masks: Wear them. If we all did so, we could cut transmission by two-thirds, perhaps even 80 percent.

Hands: Wash them.

Social distancing: If we could all stay home for two weeks, we could see enormous declines in COVID-19 transmission.

These are all time-tested solutions, proven effective ages ago in countless outbreaks of diseases including typhoid and cholera. They’re inexpensive and easy to prescribe, and the regimens are easy to follow.

The conflict between public health and individual rights and privacy, however, is less easy to resolve. Even during the pandemic of 1918–19, there was widespread resistance to mask wearing and social distancing. Fifty million people died—675,000 in the United States alone. Today, we are up to 240,000 deaths in the United States, and the end is not in sight. Antiflu measures were framed in 1918 as a way to protect the troops fighting in World War I, and people who refused to wear masks were called out as “dangerous slackers.” There was a world war, and yet it was still hard to convince people of the need for even such simple measures.

Personally, I have found the resistance to these easy fixes startling. I wouldn’t want maskless, gloveless doctors taking me through a surgical procedure. Or waltzing in from lunch without washing their hands. I’m sure you wouldn’t, either.

Science-based medicine has been one of the world’s greatest and most fundamental advances. In recent years, it has been turbocharged by breakthroughs in genetics technologies, advanced materials, high-tech diagnostics, and implants and other electronics-based interventions. Such leaps have already saved untold lives, but there’s much more to be done. And there will be many more pandemics ahead for humanity.

< Back to IEEE COVID-19 Resources Continue reading

Posted in Human Robots

#435748 Video Friday: This Robot Is Like a ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

RSS 2019 – June 22-26, 2019 – Freiburg, Germany
Hamlyn Symposium on Medical Robotics – June 23-26, 2019 – London, U.K.
ETH Robotics Summer School – June 27-1, 2019 – Zurich, Switzerland
MARSS 2019 – July 1-5, 2019 – Helsinki, Finland
ICRES 2019 – July 29-30, 2019 – London, U.K.
DARPA SubT Tunnel Circuit – August 15-22, 2019 – Pittsburgh, Pa., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.

It’s been a while since we last spoke to Joe Jones, the inventor of Roomba, about his solar-powered, weed-killing robot, called Tertill, which he was launching as a Kickstarter project. Tertill is now available for purchase (US $300) and is shipping right now.

[ Tertill ]

Usually, we don’t post videos that involve drone use that looks to be either illegal or unsafe. These flights over the protests in Hong Kong are almost certainly both. However, it’s also a unique perspective on the scale of these protests.

[ Team BlackSheep ]

ICYMI: iRobot announced this week that it has acquired Root Robotics.

[ iRobot ]

This Boston Dynamics parody video went viral this week.

The CGI is good but the gratuitous violence—even if it’s against a fake robot—is a bit too much?

This is still our favorite Boston Dynamics parody video:

[ Corridor ]

Biomedical Engineering Department Head Bin He and his team have developed the first-ever successful non-invasive mind-controlled robotic arm to continuously track a computer cursor.

[ CMU ]

Organic chemists, prepare to meet your replacement:

Automated chemical synthesis carries great promises of safety, efficiency and reproducibility for both research and industry laboratories. Current approaches are based on specifically-designed automation systems, which present two major drawbacks: (i) existing apparatus must be modified to be integrated into the automation systems; (ii) such systems are not flexible and would require substantial re-design to handle new reactions or procedures. In this paper, we propose a system based on a robot arm which, by mimicking the motions of human chemists, is able to perform complex chemical reactions without any modifications to the existing setup used by humans. The system is capable of precise liquid handling, mixing, filtering, and is flexible: new skills and procedures could be added with minimum effort. We show that the robot is able to perform a Michael reaction, reaching a yield of 34%, which is comparable to that obtained by a junior chemist (undergraduate student in Chemistry).

[ arXiv ] via [ NTU ]

So yeah, ICRA 2019 was huge and awesome. Here are some brief highlights.

[ Montreal Gazette ]

For about US $5, this drone will deliver raw meat and beer to you if you live on an uninhabited island in Tokyo Bay.

[ Nikkei ]

The Smart Microsystems Lab at Michigan State University has a new version of their Autonomous Surface Craft. It’s autonomous, open source, and awfully hard to sink.

[ SML ]

As drone shows go, this one is pretty good.

[ CCTV ]

Here’s a remote controlled robot shooting stuff with a very large gun.

[ HDT ]

Over a period of three quarters (September 2018 thru May 2019), we’ve had the opportunity to work with five graduating University of Denver students as they brought their idea for a Misty II arm extension to life.

[ Misty Robotics ]

If you wonder how it looks to inspect burners and superheaters of a boiler with an Elios 2, here you are! This inspection was performed by Svenska Elektrod in a peat-fired boiler for Vattenfall in Sweden. Enjoy!

[ Flyability ]

The newest Soft Robotics technology, mGrip mini fingers, made for tight spaces, small packaging, and delicate items, giving limitless opportunities for your applications.

[ Soft Robotics ]

What if legged robots were able to generate dynamic motions in real-time while interacting with a complex environment? Such technology would represent a significant step forward the deployment of legged systems in real world scenarios. This means being able to replace humans in the execution of dangerous tasks and to collaborate with them in industrial applications.

This workshop aims to bring together researchers from all the relevant communities in legged locomotion such as: numerical optimization, machine learning (ML), model predictive control (MPC) and computational geometry in order to chart the most promising methods to address the above-mentioned scientific challenges.

[ Num Opt Wkshp ]

Army researchers teamed with the U.S. Marine Corps to fly and test 3-D printed quadcopter prototypes a the Marine Corps Air Ground Combat Center in 29 Palms, California recently.

[ CCDC ARL ]

Lex Fridman’s Artificial Intelligence podcast featuring Rosalind Picard.

[ AI Podcast ]

In this week’s episode of Robots in Depth, per speaks with Christian Guttmann, executive director of the Nordic AI Artificial Intelligence Institute.

Christian Guttmann talks about AI and wanting to understand intelligence enough to recreate it. Christian has be focusing on AI in healthcare and has recently started to communicate the opportunities and challenges in artificial intelligence to the general public. This is something that the host Per Sjöborg is also very passionate about. We also get to hear about the Nordic AI institute and the work it does to inform all parts of society about AI.

[ Robots in Depth ] Continue reading

Posted in Human Robots

#435614 3 Easy Ways to Evaluate AI Claims

When every other tech startup claims to use artificial intelligence, it can be tough to figure out if an AI service or product works as advertised. In the midst of the AI “gold rush,” how can you separate the nuggets from the fool’s gold?

There’s no shortage of cautionary tales involving overhyped AI claims. And applying AI technologies to health care, education, and law enforcement mean that getting it wrong can have real consequences for society—not just for investors who bet on the wrong unicorn.

So IEEE Spectrum asked experts to share their tips for how to identify AI hype in press releases, news articles, research papers, and IPO filings.

“It can be tricky, because I think the people who are out there selling the AI hype—selling this AI snake oil—are getting more sophisticated over time,” says Tim Hwang, director of the Harvard-MIT Ethics and Governance of AI Initiative.

The term “AI” is perhaps most frequently used to describe machine learning algorithms (and deep learning algorithms, which require even less human guidance) that analyze huge amounts of data and make predictions based on patterns that humans might miss. These popular forms of AI are mostly suited to specialized tasks, such as automatically recognizing certain objects within photos. For that reason, they are sometimes described as “weak” or “narrow” AI.

Some researchers and thought leaders like to talk about the idea of “artificial general intelligence” or “strong AI” that has human-level capacity and flexibility to handle many diverse intellectual tasks. But for now, this type of AI remains firmly in the realm of science fiction and is far from being realized in the real world.

“AI has no well-defined meaning and many so-called AI companies are simply trying to take advantage of the buzz around that term,” says Arvind Narayanan, a computer scientist at Princeton University. “Companies have even been caught claiming to use AI when, in fact, the task is done by human workers.”

Here are three ways to recognize AI hype.

Look for Buzzwords
One red flag is what Hwang calls the “hype salad.” This means stringing together the term “AI” with many other tech buzzwords such as “blockchain” or “Internet of Things.” That doesn’t automatically disqualify the technology, but spotting a high volume of buzzwords in a post, pitch, or presentation should raise questions about what exactly the company or individual has developed.

Other experts agree that strings of buzzwords can be a red flag. That’s especially true if the buzzwords are never really explained in technical detail, and are simply tossed around as vague, poorly-defined terms, says Marzyeh Ghassemi, a computer scientist and biomedical engineer at the University of Toronto in Canada.

“I think that if it looks like a Google search—picture ‘interpretable blockchain AI deep learning medicine’—it's probably not high-quality work,” Ghassemi says.

Hwang also suggests mentally replacing all mentions of “AI” in an article with the term “magical fairy dust.” It’s a way of seeing whether an individual or organization is treating the technology like magic. If so—that’s another good reason to ask more questions about what exactly the AI technology involves.

And even the visual imagery used to illustrate AI claims can indicate that an individual or organization is overselling the technology.

“I think that a lot of the people who work on machine learning on a day-to-day basis are pretty humble about the technology, because they’re largely confronted with how frequently it just breaks and doesn't work,” Hwang says. “And so I think that if you see a company or someone representing AI as a Terminator head, or a big glowing HAL eye or something like that, I think it’s also worth asking some questions.”

Interrogate the Data

It can be hard to evaluate AI claims without any relevant expertise, says Ghassemi at the University of Toronto. Even experts need to know the technical details of the AI algorithm in question and have some access to the training data that shaped the AI model’s predictions. Still, savvy readers with some basic knowledge of applied statistics can search for red flags.

To start, readers can look for possible bias in training data based on small sample sizes or a skewed population that fails to reflect the broader population, Ghassemi says. After all, an AI model trained only on health data from white men would not necessarily achieve similar results for other populations of patients.

“For me, a red flag is not demonstrating deep knowledge of how your labels are defined.”
—Marzyeh Ghassemi, University of Toronto

How machine learning and deep learning models perform also depends on how well humans labeled the sample datasets use to train these programs. This task can be straightforward when labeling photos of cats versus dogs, but gets more complicated when assigning disease diagnoses to certain patient cases.

Medical experts frequently disagree with each other on diagnoses—which is why many patients seek a second opinion. Not surprisingly, this ambiguity can also affect the diagnostic labels that experts assign in training datasets. “For me, a red flag is not demonstrating deep knowledge of how your labels are defined,” Ghassemi says.

Such training data can also reflect the cultural stereotypes and biases of the humans who labeled the data, says Narayanan at Princeton University. Like Ghassemi, he recommends taking a hard look at exactly what the AI has learned: “A good way to start critically evaluating AI claims is by asking questions about the training data.”

Another red flag is presenting an AI system’s performance through a single accuracy figure without much explanation, Narayanan says. Claiming that an AI model achieves “99 percent” accuracy doesn’t mean much without knowing the baseline for comparison—such as whether other systems have already achieved 99 percent accuracy—or how well that accuracy holds up in situations beyond the training dataset.

Narayanan also emphasized the need to ask questions about an AI model’s false positive rate—the rate of making wrong predictions about the presence of a given condition. Even if the false positive rate of a hypothetical AI service is just one percent, that could have major consequences if that service ends up screening millions of people for cancer.

Readers can also consider whether using AI in a given situation offers any meaningful improvement compared to traditional statistical methods, says Clayton Aldern, a data scientist and journalist who serves as managing director for Caldern LLC. He gave the hypothetical example of a “super-duper-fancy deep learning model” that achieves a prediction accuracy of 89 percent, compared to a “little polynomial regression model” that achieves 86 percent on the same dataset.

“We're talking about a three-percentage-point increase on something that you learned about in Algebra 1,” Aldern says. “So is it worth the hype?”

Don’t Ignore the Drawbacks

The hype surrounding AI isn’t just about the technical merits of services and products driven by machine learning. Overblown claims about the beneficial impacts of AI technology—or vague promises to address ethical issues related to deploying it—should also raise red flags.

“If a company promises to use its tech ethically, it is important to question if its business model aligns with that promise,” Narayanan says. “Even if employees have noble intentions, it is unrealistic to expect the company as a whole to resist financial imperatives.”

One example might be a company with a business model that depends on leveraging customers’ personal data. Such companies “tend to make empty promises when it comes to privacy,” Narayanan says. And, if companies hire workers to produce training data, it’s also worth asking whether the companies treat those workers ethically.

The transparency—or lack thereof—about any AI claim can also be telling. A company or research group can minimize concerns by publishing technical claims in peer-reviewed journals or allowing credible third parties to evaluate their AI without giving away big intellectual property secrets, Narayanan says. Excessive secrecy is a big red flag.

With these strategies, you don’t need to be a computer engineer or data scientist to start thinking critically about AI claims. And, Narayanan says, the world needs many people from different backgrounds for societies to fully consider the real-world implications of AI.

Editor’s Note: The original version of this story misspelled Clayton Aldern’s last name as Alderton. Continue reading

Posted in Human Robots

#435098 Coming of Age in the Age of AI: The ...

The first generation to grow up entirely in the 21st century will never remember a time before smartphones or smart assistants. They will likely be the first children to ride in self-driving cars, as well as the first whose healthcare and education could be increasingly turned over to artificially intelligent machines.

Futurists, demographers, and marketers have yet to agree on the specifics of what defines the next wave of humanity to follow Generation Z. That hasn’t stopped some, like Australian futurist Mark McCrindle, from coining the term Generation Alpha, denoting a sort of reboot of society in a fully-realized digital age.

“In the past, the individual had no power, really,” McCrindle told Business Insider. “Now, the individual has great control of their lives through being able to leverage this world. Technology, in a sense, transformed the expectations of our interactions.”

No doubt technology may impart Marvel superhero-like powers to Generation Alpha that even tech-savvy Millennials never envisioned over cups of chai latte. But the powers of machine learning, computer vision, and other disciplines under the broad category of artificial intelligence will shape this yet unformed generation more definitively than any before it.

What will it be like to come of age in the Age of AI?

The AI Doctor Will See You Now
Perhaps no other industry is adopting and using AI as much as healthcare. The term “artificial intelligence” appears in nearly 90,000 publications from biomedical literature and research on the PubMed database.

AI is already transforming healthcare and longevity research. Machines are helping to design drugs faster and detect disease earlier. And AI may soon influence not only how we diagnose and treat illness in children, but perhaps how we choose which children will be born in the first place.

A study published earlier this month in NPJ Digital Medicine by scientists from Weill Cornell Medicine used 12,000 photos of human embryos taken five days after fertilization to train an AI algorithm on how to tell which in vitro fertilized embryo had the best chance of a successful pregnancy based on its quality.

Investigators assigned each embryo a grade based on various aspects of its appearance. A statistical analysis then correlated that grade with the probability of success. The algorithm, dubbed Stork, was able to classify the quality of a new set of images with 97 percent accuracy.

“Our algorithm will help embryologists maximize the chances that their patients will have a single healthy pregnancy,” said Dr. Olivier Elemento, director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine, in a press release. “The IVF procedure will remain the same, but we’ll be able to improve outcomes by harnessing the power of artificial intelligence.”

Other medical researchers see potential in applying AI to detect possible developmental issues in newborns. Scientists in Europe, working with a Finnish AI startup that creates seizure monitoring technology, have developed a technique for detecting movement patterns that might indicate conditions like cerebral palsy.

Published last month in the journal Acta Pediatrica, the study relied on an algorithm to extract the movements from a newborn, turning it into a simplified “stick figure” that medical experts could use to more easily detect clinically relevant data.

The researchers are continuing to improve the datasets, including using 3D video recordings, and are now developing an AI-based method for determining if a child’s motor maturity aligns with its true age. Meanwhile, a study published in February in Nature Medicine discussed the potential of using AI to diagnose pediatric disease.

AI Gets Classy
After being weaned on algorithms, Generation Alpha will hit the books—about machine learning.

China is famously trying to win the proverbial AI arms race by spending billions on new technologies, with one Chinese city alone pledging nearly $16 billion to build a smart economy based on artificial intelligence.

To reach dominance by its stated goal of 2030, Chinese cities are also incorporating AI education into their school curriculum. Last year, China published its first high school textbook on AI, according to the South China Morning Post. More than 40 schools are participating in a pilot program that involves SenseTime, one of the country’s biggest AI companies.

In the US, where it seems every child has access to their own AI assistant, researchers are just beginning to understand how the ubiquity of intelligent machines will influence the ways children learn and interact with their highly digitized environments.

Sandra Chang-Kredl, associate professor of the department of education at Concordia University, told The Globe and Mail that AI could have detrimental effects on learning creativity or emotional connectedness.

Similar concerns inspired Stefania Druga, a member of the Personal Robots group at the MIT Media Lab (and former Education Teaching Fellow at SU), to study interactions between children and artificial intelligence devices in order to encourage positive interactions.

Toward that goal, Druga created Cognimates, a platform that enables children to program and customize their own smart devices such as Alexa or even a smart, functional robot. The kids can also use Cognimates to train their own AI models or even build a machine learning version of Rock Paper Scissors that gets better over time.

“I believe it’s important to also introduce young people to the concepts of AI and machine learning through hands-on projects so they can make more informed and critical use of these technologies,” Druga wrote in a Medium blog post.

Druga is also the founder of Hackidemia, an international organization that sponsors workshops and labs around the world to introduce kids to emerging technologies at an early age.

“I think we are in an arms race in education with the advancement of technology, and we need to start thinking about AI literacy before patterns of behaviors for children and their families settle in place,” she wrote.

AI Goes Back to School
It also turns out that AI has as much to learn from kids. More and more researchers are interested in understanding how children grasp basic concepts that still elude the most advanced machine minds.

For example, developmental psychologist Alison Gopnik has written and lectured extensively about how studying the minds of children can provide computer scientists clues on how to improve machine learning techniques.

In an interview on Vox, she described that while DeepMind’s AlpahZero was trained to be a chessmaster, it struggles with even the simplest changes in the rules, such as allowing the bishop to move horizontally instead of vertically.

“A human chess player, even a kid, will immediately understand how to transfer that new rule to their playing of the game,” she noted. “Flexibility and generalization are something that even human one-year-olds can do but that the best machine learning systems have a much harder time with.”

Last year, the federal defense agency DARPA announced a new program aimed at improving AI by teaching it “common sense.” One of the chief strategies is to develop systems for “teaching machines through experience, mimicking the way babies grow to understand the world.”

Such an approach is also the basis of a new AI program at MIT called the MIT Quest for Intelligence.

The research leverages cognitive science to understand human intelligence, according to an article on the project in MIT Technology Review, such as exploring how young children visualize the world using their own innate 3D models.

“Children’s play is really serious business,” said Josh Tenenbaum, who leads the Computational Cognitive Science lab at MIT and his head of the new program. “They’re experiments. And that’s what makes humans the smartest learners in the known universe.”

In a world increasingly driven by smart technologies, it’s good to know the next generation will be able to keep up.

Image Credit: phoelixDE / Shutterstock.com Continue reading

Posted in Human Robots